Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis

Drug Design, Development and Therapy

Volumn , Issue 5, 2011, Pages 77-84

  Ono, Santa J ^a   Lane, Keith ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ora Inc   (United States)

Author keywords

Alcaftadine; Ocular allergy; Olopatadine

Indexed keywords

ALCAFTADINE; OLOPATADINE; PROTEIN ZO1; UVOMORULIN; ANTIALLERGIC AGENT; BENZAZEPINE DERIVATIVE; DIBENZOXEPIN DERIVATIVE; IMIDAZOLE DERIVATIVE; MEMBRANE PROTEIN; PHOSPHOPROTEIN; ZONULA OCCLUDENS-1 PROTEIN;

ACUTE PHASE RESPONSE; ALLERGIC CONJUNCTIVITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFECT; DRUG EFFICACY; EOSINOPHIL COUNT; IN VITRO STUDY; MAST CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; BAGG ALBINO MOUSE; COMPARATIVE STUDY; CONJUNCTIVA; DISEASE MODEL; EOSINOPHIL; EPITHELIUM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TIGHT JUNCTION; TIME;

ANIMALS; ANTI-ALLERGIC AGENTS; BENZAZEPINES; CONJUNCTIVA; CONJUNCTIVITIS, ALLERGIC; DIBENZOXEPINS; DISEASE MODELS, ANIMAL; EOSINOPHILS; EPITHELIUM; GENE EXPRESSION REGULATION; IMIDAZOLES; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; PHOSPHOPROTEINS; TIGHT JUNCTIONS; TIME FACTORS;

EID: 79952905429     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S15788     Document Type: Article

References (19)

1. Ciprandi G, Buscaglia S, Cerqueti PM, Canonica GW. Drug treatment of allergic conjunctivitis. A review of the evidence. Drugs. 1992;43: 154-176.
2. Uchio E, Kimura R, Migita H, Kozawa M, Kadonosono K. Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy. Graefes Arch Clin Exp Ophthalmol. 2008;246:291-296.
3. Abelson MB, Smith L, Chapin M. Ocular allergic disease: Mechanisms, disease sub-types, treatment. Ocul Surf. 2003;1:127-149.
4. Aijaz S, Balda MS, Matter K, Kwang WJ. Tight junctions: Molecular architecture and function. In: International Review of Cytology. New York, NY: Academic Press; 2006.
5. Hughes JL, Lackie PM, Wilson SJ, Church MK, McGill JI. Reduced structural proteins in the conjunctival epithelium in allergic eye disease. Allergy. 2006;61:1268-1274.
6. Wan H, Winton HL, Soeller C, et al. The transmembrane protein occluding of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus. Clin Exp Allergy. 2001;31:279-294.
7. Runswick S, Mitchell T, Davies P, Robinson C, Garrod DR. Pollen proteolytic enzymes degrade tight junctions. Respirology. 2007;12: 834-842.
8. Abramowicz M, editor. Drugs for allergic disorders. Medical Letter Treatment Guidelines. 2010;8:9-18.
9. Rubenstein NM, Guan Y, Woo PL, Firestone GL. Glucocorticoid downregulation of RhoA is required for the steroid-induced organization of the junctional complex and tight junction formation in rat mammary epithelial tumor cells. J Biol Chem. 2003;278:10353-10360.
10. Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2003;293:L660-L667.
11. Bohets H, McGowan C, Mannens G, Schroeder N, Edwards-Swanson K, Shapiro A. Clinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis. 2011 J. Ocul. Pharm Ther. In press.
12. 4 histamine receptors. Personal communication.
13. Ohmori K, Hayashi K, Kaise T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002;88:379-397.
14. Fukuishi N, Matsuhisa M, Shimono T, et al. Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils. Jpn J Pharmacol. 2002;88: 463-466.
15. Miyazaki D, Nakamura T, Ohbayashi M, et al. Ablation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1/ CCR3 blockade. Int Immunol. 2009;21:187-201.
16. Ling P, Ngo K, Nguyen S, et al. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule up regulation. Br J Pharmacol. 2004;142:161-171.
17. Brockman HL, Momsen MM, Knudtson JR, Miller ST, Graff G, Yanni JM. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul Immunol Inflamm. 2003;11: 247-268.
18. Terada N, Hamano N, Numata T, Konno A. Transepithelial migration of activated eosinophils induces a decrease of E-cadherin expression in cultured human nasal epithelial cells. Clin Exp Allergy. 2000;30: 807-817.
19. Kobayashi N, Dezawa M, Nagata H, Yuasa S, Konno A. Immunohistochemical study of E-cadherin and ZO1 in allergic nasal epithelium of the guinea pig. Int Arch Allergy Immunol. 1998;116:196-205.